A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 771-778

  Martinez Balibrea, Eva ^a,b   Plasencia, Carmen ^b,c   Ginés, Alba ^a   Martinez Cardús, Anna ^a   Musulén, Eva ^a   Aguilera, Rodrigo ^b,d   Manzano, José Luis ^a   Neamati, Nouri ^b   Abad, Albert ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Applied Biosystems   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; FLUOROURACIL; ISOPROTEIN; MESSENGER RNA; OXALIPLATIN; PROTEIN P53; PYRUVATE KINASE; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; TP53 PROTEIN, HUMAN;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; COLORECTAL TUMOR; DRUG RESISTANCE; ENZYME IMMUNOASSAY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL CULTURE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CISPLATIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROTEOMICS; PYRUVATE KINASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 66449086209     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0882     Document Type: Article

References (23)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-584
2. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23. (Pubitemid 46137553)
3. Martinez-Balibrea E, Abad A, Aranda E, et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 2008;44:1229-1237
4. Martinez-Cardús A, Martinez-Balibrea E, Bandrés E, et al. Pharmacogenomic approach for the identification of novel determinants of resistance to oxaliplatin in colon cancer. Mol Cancer 2009;8:194-202.
5. Plebani M. Proteomics: the next revolution in laboratory medicine? Clin ChimActa 2005;357:113-122
6. Steták A, Veress R, Ovadi J, Csermely P, Keri G, Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res 2007;67:1602-1608 (Pubitemid 46383385)
7. Plasencia C, Martinez-Balibrea E, Martinez-Cardus A, Quinn DI, Abad A, Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol 2006;29:225-235
8. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601. (Pubitemid 18056527)
9. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004;13: 2443-2449 (Pubitemid 39377848)
10. Tanaka T, Harano Y, Sue F, Morimura H. Crystallization, characterization and metabolic regulation of two types of pyruvate kinase isolated fromrat tissues. J Biochem(T okyo) 1967;62:71-91.
11. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15:300-308 (Pubitemid 41058775)
12. Vertessy BG, Bankfalvi D, Kovacs J, Low P, Lehotzky A, Ovadi J. Pyruvate kinase as a microtubule destabilizing factor in vitro. Biochem Biophys Res Commun 1999;254:430-435 (Pubitemid 29290417)
13. Dastoor Z, Dreyer JL. Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress. J Cell Sci 2001;114:1643-1653 (Pubitemid 32454663)
14. Sawa A, Khan AA, Hester LD, Snyder SH. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. Proc Natl Acad Sci U S A 1997;94:11669-11674 (Pubitemid 27451056)
15. Ronai Z. Glycolytic enzymes as DNA binding proteins. Int J Biochem 1993;25:1073-1076 (Pubitemid 23186514)
16. Tarze A, Deniaud A, Le Bras M, et al. GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene 2007; 26:2606-2620 (Pubitemid 46632015)
17. Hoshino A, Hirst JA, Fujii H. Regulation of cell proliferation by interleukin- 3-induced nuclear translocation of pyruvate kinase. J Biol Chem 2007;282:17706-17711 (Pubitemid 47100326)
18. Yoo BC, Ku JL, Hong SH, et al. Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer 2004;108:532-539 (Pubitemid 38036653)
19. Nicotera P, Leist M. Energy supply and the shape of death in neurons and lymphoid cells. Cell Death Differ 1997;4:435-442 (Pubitemid 127680678)
20. Nicotera P, Leist M. Mitochondrial signals and energy requirement in cell death. Cell Death Differ 1997;4:516.
21. Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43:1348-1360 (Pubitemid 46874070)
22. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008;452: 181-186
23. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230-233